A Pill or Injection for Clearing Atopic Skin? Real World Insights with Dr.Ashley O'Toole
Episode Learning Objectives
· Explore assessment strategies based on disease activity to guide treatment decisions for moderate to severe atopic dermatitis
· Apply current evidence as well as shared decision-making to individualize therapy decisions for patients with moderate to severe atopic dermatitis; specifically real world experience around dupilumab (DUPIXENT) and a recent publication exploring upadacitinib (RINVOQ), an experimental indication for AD vs dupilumab
· Implement strategies to improve interprofessional care coordination between primary care providers and specialty care providers and address the unmet needs of patients
ABOUT DR.ASHLEY O'TOOLE, MHSc, MD, FRCPC:
Dr. O’Toole is a dermatologist with the SKiN Centre for Dermatology in Peterborough, Ontario where she also serves as a sub-investigator for multiple clinical trials. She is an adjunctive professor at Queens University and involved in teaching medical students and residents and holds medical privileges at the Peterborough Regional Health Centre.
After receiving a Master’s of Health Science in Health and Behavioural Communication at Ryerson University in Toronto, Ontario, Dr. O’Toole received her medical degree from McMaster University in Hamilton, Ontario, and completed her residency in dermatology at the University of Ottawa in Ottawa, Ontario.
Dr. O’Toole is the author or co-author of over 20 peer-reviewed publications and has been involved ias a sub-investigator for over 40 clinical trials on atopic dermatitis, psoriasis, alopecia, acne and vitiligo.
Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.
Discussed:
Supported by IMEs from Janssen and Lilly
www.skinandjoints.ca
📻www.skinandjoints.ca
✉️info@skinandjoints.ca
Create your
podcast in
minutes
It is Free